Stocklytics Platform
Asset logo for symbol CRSP
CRISPR Therapeutics AG
CRSP64
$40.72arrow_drop_up0.80%$0.32
Asset logo for symbol CRSP
CRSP64

$40.72

arrow_drop_up0.80%

Income Statement (CRSP)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$110.19M-$151.26M-$140.58M$69.58M-$137.33M
EBITDA-$105.39M-$146.41M-$135.75M$74.48M-$132.41M
gross Profit-$10.55M-$56.45M-$51.29M$180.00M-$23.42M
NET Income-$85.94M-$126.40M-$116.59M$89.34M-$112.15M
total Revenue$602.00K$517.00K$504.00K$200.00M$0.00

Balance Sheet (CRSP)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt$1.87M-$253.16M-$472.50M-$150.84M-$286.17M
stockholders Equity$1.93B$1.98B$2.08B$1.88B$1.72B
total Assets$2.25B$2.33B$2.43B$2.22B$2.08B
total Debt$227.54M$231.30M$234.92M$238.63M$241.58M
total Liabilities$316.47M$358.90M$355.08M$346.76M$359.03M

Cash Flow (CRSP)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$9.64M-$466.00K$305.93M$38.93M$1.55M
free Cash Flow-$107.13M-$96.28M$109.03M-$96.81M-$41.97M
investing Cash Flow-----
operating Cash Flow-$106.91M-$95.58M$109.75M-$96.07M-$39.85M

CRISPR Therapeutics AG (CRSP) Financials

The income statement of CRISPR Therapeutics AG (CRSP) provides a comprehensive overview of the company's financial performance. It shows the revenue generated by the company, as well as the costs and expenses incurred. The income statement includes various key figures, such as gross profit, operating income, and net income. These figures reflect the profitability of the company and its ability to generate profits from its operations. Additionally, the income statement also provides information on earnings before interest and taxes (EBIT) and earnings before interest, taxes, depreciation, and amortization (EBITDA).
The balance sheet of CRISPR Therapeutics AG (CRSP) provides a snapshot of the company's financial position at a specific point in time. It shows the company's assets, liabilities, and stockholders' equity. The balance sheet is divided into two main sections: assets and liabilities. The assets section includes cash, cash equivalents, and other assets, while the liabilities section includes debt and other liabilities. The balance sheet provides valuable information about the company's liquidity, solvency, and the value of its investments. Furthermore, it also shows the company's net debt, which is calculated by subtracting cash and cash equivalents from total debt. The stockholders' equity represents the owners' interest in the company and is calculated by subtracting total liabilities from total assets.
The cash flow statement of CRISPR Therapeutics AG (CRSP) provides information about the company's cash inflows and outflows during a specific period. It includes three main sections: operating activities, investing activities, and financing activities. The operating activities section shows the cash generated or used in the company's core operations, such as revenue from sales and payments to suppliers. The investing activities section shows the cash used for acquisitions, investments in property and equipment, and other long-term assets. The financing activities section shows the cash generated or used from activities such as issuing or repurchasing stock, borrowing or repaying debt, and paying dividends. The cash flow statement is crucial in assessing the company's ability to generate cash and its overall financial health. Lastly, the statement provides information on free cash flow, which is calculated by subtracting capital expenditures from operating cash flow. Free cash flow represents the cash available to the company after investing in its core operations and maintaining its assets.
add CRISPR Therapeutics AG to watchlist

Keep an eye on CRISPR Therapeutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level